These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

730 related articles for article (PubMed ID: 14984767)

  • 1. Endothelial cell integrins and COX-2: mediators and therapeutic targets of tumor angiogenesis.
    Rüegg C; Dormond O; Mariotti A
    Biochim Biophys Acta; 2004 Mar; 1654(1):51-67. PubMed ID: 14984767
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regulation of endothelial cell integrin function and angiogenesis by COX-2, cAMP and Protein Kinase A.
    Dormond O; Rüegg C
    Thromb Haemost; 2003 Oct; 90(4):577-85. PubMed ID: 14515176
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Suppression of tumor angiogenesis through the inhibition of integrin function and signaling in endothelial cells: which side to target?
    Rüegg C; Dormond O; Foletti A
    Endothelium; 2002; 9(3):151-60. PubMed ID: 12380640
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vascular integrins: pleiotropic adhesion and signaling molecules in vascular homeostasis and angiogenesis.
    Rüegg C; Mariotti A
    Cell Mol Life Sci; 2003 Jun; 60(6):1135-57. PubMed ID: 12861381
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vascular integrins: therapeutic and imaging targets of tumor angiogenesis.
    Rüegg C; Alghisi GC
    Recent Results Cancer Res; 2010; 180():83-101. PubMed ID: 20033379
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Integrin-mediated adhesion and soluble ligand binding stabilize COX-2 protein levels in endothelial cells by inducing expression and preventing degradation.
    Zaric J; Rüegg C
    J Biol Chem; 2005 Jan; 280(2):1077-85. PubMed ID: 15525653
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cyclooxygenase-2: a therapeutic target in angiogenesis.
    Iñiguez MA; Rodríguez A; Volpert OV; Fresno M; Redondo JM
    Trends Mol Med; 2003 Feb; 9(2):73-8. PubMed ID: 12615041
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cerebral ischemia-induced angiogenesis is dependent on tumor necrosis factor receptor 1-mediated upregulation of α5β1 and αVβ3 integrins.
    Huang H; Huang Q; Wang F; Milner R; Li L
    J Neuroinflammation; 2016 Sep; 13(1):227. PubMed ID: 27586239
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic potential of selective cyclooxygenase-2 inhibitors in the management of tumor angiogenesis.
    Gately S; Kerbel R
    Prog Exp Tumor Res; 2003; 37():179-92. PubMed ID: 12795055
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction of cyclooxygenase-1 and -2 modulates angiogenic responses to engagement of alphavbeta3.
    Murphy JF; Steele C; Belton O; Fitzgerald DJ
    Br J Haematol; 2003 Apr; 121(1):157-64. PubMed ID: 12670347
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vascular integrins in tumor angiogenesis: mediators and therapeutic targets.
    Alghisi GC; Rüegg C
    Endothelium; 2006; 13(2):113-35. PubMed ID: 16728329
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NSAIDs inhibit alpha V beta 3 integrin-mediated and Cdc42/Rac-dependent endothelial-cell spreading, migration and angiogenesis.
    Dormond O; Foletti A; Paroz C; Rüegg C
    Nat Med; 2001 Sep; 7(9):1041-7. PubMed ID: 11533708
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cyclooxygenase inhibitors suppress angiogenesis and reduce tumor growth in vivo.
    Sawaoka H; Tsuji S; Tsujii M; Gunawan ES; Sasaki Y; Kawano S; Hori M
    Lab Invest; 1999 Dec; 79(12):1469-77. PubMed ID: 10616198
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cyclooxygenase-2-selective nonsteroidal anti-inflammatory drugs inhibit hepatocyte growth factor/scatter factor-induced angiogenesis.
    Sengupta S; Sellers LA; Cindrova T; Skepper J; Gherardi E; Sasisekharan R; Fan TP
    Cancer Res; 2003 Dec; 63(23):8351-9. PubMed ID: 14678996
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulation of COX-2 mediated signaling by alpha3 type IV noncollagenous domain in tumor angiogenesis.
    Boosani CS; Mannam AP; Cosgrove D; Silva R; Hodivala-Dilke KM; Keshamouni VG; Sudhakar A
    Blood; 2007 Aug; 110(4):1168-77. PubMed ID: 17426256
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The contributions of cyclooxygenase-2 to tumor angiogenesis.
    Gately S
    Cancer Metastasis Rev; 2000; 19(1-2):19-27. PubMed ID: 11191059
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The biology of integrins.
    Stupack DG
    Oncology (Williston Park); 2007 Aug; 21(9 Suppl 3):6-12. PubMed ID: 17927025
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lebectin, a Macrovipera lebetina venom-derived C-type lectin, inhibits angiogenesis both in vitro and in vivo.
    Pilorget A; Conesa M; Sarray S; Michaud-Levesque J; Daoud S; Kim KS; Demeule M; Marvaldi J; El Ayeb M; Marrakchi N; Béliveau R; Luis J
    J Cell Physiol; 2007 May; 211(2):307-15. PubMed ID: 17323383
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulation of tumor angiogenesis by fastatin, the fourth FAS1 domain of betaig-h3, via alphavbeta3 integrin.
    Nam JO; Jeong HW; Lee BH; Park RW; Kim IS
    Cancer Res; 2005 May; 65(10):4153-61. PubMed ID: 15899806
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Integrin-Targeted Peptide- and Peptidomimetic-Drug Conjugates for the Treatment of Tumors.
    Arosio D; Manzoni L; Corno C; Perego P
    Recent Pat Anticancer Drug Discov; 2017; 12(2):148-168. PubMed ID: 28164756
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.